134 related articles for article (PubMed ID: 20966892)
21. JAK2 inhibitors: what's the true therapeutic potential?
Santos FP; Verstovsek S
Blood Rev; 2011 Mar; 25(2):53-63. PubMed ID: 21095048
[TBL] [Abstract][Full Text] [Related]
22. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
23. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
24. New JAK2 inhibitors for myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
[TBL] [Abstract][Full Text] [Related]
25. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Atallah E; Verstovsek S
Expert Rev Anticancer Ther; 2009 May; 9(5):663-70. PubMed ID: 19445582
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
27. Janus kinase mutations.
Levine RL
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S6-11. PubMed ID: 19393837
[TBL] [Abstract][Full Text] [Related]
28. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases.
Hitoshi Y; Lin N; Payan DG; Markovtsov V
Int J Hematol; 2010 Mar; 91(2):189-200. PubMed ID: 20191331
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
30. Novel strategies for patients with chronic myeloproliferative disorders.
Barosi G; Rosti V
Curr Opin Hematol; 2009 Mar; 16(2):129-34. PubMed ID: 19468275
[TBL] [Abstract][Full Text] [Related]
31. Myeloproliferative disorders.
Levine RL; Gilliland DG
Blood; 2008 Sep; 112(6):2190-8. PubMed ID: 18779404
[TBL] [Abstract][Full Text] [Related]
32. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Santos FP; Verstovsek S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
[TBL] [Abstract][Full Text] [Related]
33. JAK2 inhibitors: A reality? A hope?
Apostolidou E; Kantarjian HM; Verstovsek S
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S340-5. PubMed ID: 19778862
[TBL] [Abstract][Full Text] [Related]
34. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.
Wernig G; Kharas MG; Mullally A; Leeman DS; Okabe R; George T; Clary DO; Gilliland DG
Leukemia; 2012 Apr; 26(4):720-7. PubMed ID: 22005786
[TBL] [Abstract][Full Text] [Related]
35. R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.
Shide K; Kameda T; Markovtsov V; Shimoda HK; Tonkin E; Fang S; Liu C; Gelman M; Lang W; Romero J; McLaughlin J; Bhamidipati S; Clough J; Low C; Reitsma A; Siu S; Pine P; Park G; Torneros A; Duan M; Singh R; Payan DG; Matsunaga T; Hitoshi Y; Shimoda K
Blood; 2011 Jun; 117(25):6866-75. PubMed ID: 21531978
[TBL] [Abstract][Full Text] [Related]
36. Targeting JAK2 in the therapy of myeloproliferative neoplasms.
Reddy MM; Deshpande A; Sattler M
Expert Opin Ther Targets; 2012 Mar; 16(3):313-24. PubMed ID: 22339244
[TBL] [Abstract][Full Text] [Related]
37. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt.
Mishchenko E; Tefferi A
Eur J Haematol; 2010 Sep; 85(3):192-9. PubMed ID: 20528907
[TBL] [Abstract][Full Text] [Related]
38. Recent developments on JAK2 inhibitors: a patent review.
Kiss R; Sayeski PP; Keserũ GM
Expert Opin Ther Pat; 2010 Apr; 20(4):471-95. PubMed ID: 20205617
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?
Constantinescu SN; Vainchenker W
Hematology Am Soc Hematol Educ Program; 2012; 2012():553-60. PubMed ID: 23233634
[TBL] [Abstract][Full Text] [Related]
40. Real-time bioluminescence imaging of polycythemia vera development in mice.
Ma Y; Zhao S; Zhu J; Bettano KA; Qu X; Marshall CG; Young JR; Kohl NE; Scott ML; Zhang W; Wang Y
Biochim Biophys Acta; 2009 Nov; 1792(11):1073-9. PubMed ID: 19715759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]